Sanofi, Re­gen­eron build their case for yet an­oth­er ap­proval for im­munol­o­gy star Dupix­ent

Over the week­end Sanofi and Re­gen­eron post­ed an­oth­er up­beat round of da­ta from their Phase III pro­gram for the pow­er­house Dupix­ent — this time in eosinophilic esophagi­tis. And they made it clear that they’ll be us­ing the re­sults to hunt yet an­oth­er reg­u­la­to­ry nod for the mega block­buster fran­chise this year.

Re­searchers for the part­ners turned out at the 2022 AAAAI an­nu­al meet­ing to tout a 64% re­duc­tion in dis­ease symp­toms from base­line com­pared to 41% for place­bo. They added:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.